Oxford PharmaScience Advances Partnership Discussions for Oxprofen Platform
September 2025

Oxford PharmaScience is advancing development of its Oxprofen™ fast-acting ibuprofen platform, following successful confirmation of API manufacturing economics at commercial scale and the development of a fully taste-masked, fast-acting orally dispersible tablet (ODT) format.

In parallel, the company is progressing additional intellectual-property filings covering next-generation formulations designed to further enhance the speed and consumer experience of fast-acting oral analgesics.

Oxford PharmaScience is currently in confidential discussions with several leading pharmaceutical companies to develop and commercialize the Oxprofen platform across prescription and over-the-counter pain-relief markets.

Regulatory pathways for the LDH-based formulation remain well established, enabling streamlined registration via 505(b)(2) and hybrid procedures, as well as direct OTC routes where appropriate.

Further updates will be provided as development and partnership discussions progress.